<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00273273</url>
  </required_header>
  <id_info>
    <org_study_id>ATN 056</org_study_id>
    <nct_id>NCT00273273</nct_id>
  </id_info>
  <brief_title>PK of Once Daily ART Containing Tenofovir and Atazanavir/Ritonavir</brief_title>
  <official_title>Pharmacokinetics of Once Daily Antiretroviral Therapy Regimens Containing Tenofovir and Atazanavir/Ritonavir in Adolescents and Young Adults With HIV Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of North Carolina, Chapel Hill</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this project is to study the pharmacokinetics of a once-daily antiretroviral&#xD;
      medication used to treat adolescents and young adults with HIV infection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Once-daily antiretroviral therapy is being used to treat adolescents and young adults with&#xD;
      HIV-1 infection. When new antiretrovirals (ARVs) are developed, information on kinetics is&#xD;
      collected in adults, and then in children, but often the adolescent age group is&#xD;
      under-represented in initial or even later pharmacokinetics studies, so specific data on&#xD;
      appropriate drug doses to use in adolescents may be lacking; it is assumed that they should&#xD;
      receive the adult dose. Furthermore, as newer drugs are used in combination regimens, more&#xD;
      information becomes available on drug interactions that might not have been initially&#xD;
      anticipated. This information is usually generated in studies of adults, with little or no&#xD;
      specific information in children or adolescents. This is an open-label, 24-hour, single-dose&#xD;
      pharmacokinetic study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Measure the pharmacokinetics of atazanavir/ritonavir and tenofovir</measure>
    <time_frame>6 Months</time_frame>
    <description>To measure the pharmacokinetics of atazanavir/ritonavir and tenofovir when used in combination to treat HIV-infected adolescents and young adult subjects</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Kinetics comparison</measure>
    <time_frame>6 Months</time_frame>
    <description>To compare the kinetics in these study subjects with published kinetics profiles in adults and children.</description>
  </secondary_outcome>
  <enrollment>30</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>blood draw</intervention_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Persons with HIV-1 infection between the ages of 18 years, 0 days and 24 years, 364 days&#xD;
        currently on a stable combination antiretroviral regimen (&gt; 28 days) with FDA-approved&#xD;
        antiretroviral combination regimens that include tenofovir plus atazanavir/ritonavir and at&#xD;
        least one other active antiretroviral drug.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 18 year to &lt; 25 years.&#xD;
&#xD;
          -  Confirmed diagnosis of HIV-1 infection defined as one positive assay supported by&#xD;
             documentation from the subject's medical record. The result may be any of the&#xD;
             following:&#xD;
&#xD;
          -  HIV-1 DNA PCR,&#xD;
&#xD;
          -  HIV-1 RNA PCR (&gt; 5,000 copies/ml),&#xD;
&#xD;
          -  Standard ELISA with confirmatory western blot performed after 18 months of age, or&#xD;
&#xD;
          -  HIV culture.&#xD;
&#xD;
          -  CD4 cell count: no restrictions.&#xD;
&#xD;
          -  Viral load: no restrictions.&#xD;
&#xD;
          -  Current treatment with stable antiretroviral combination therapy with at least 3&#xD;
             active drugs for a minimum of 28 days. The treatment regimen will not be started or&#xD;
             changed for the purposes of participation in this study. Rather, this study will&#xD;
             measure kinetics of the drugs in patients who have been receiving therapy at the&#xD;
             direction of their treating physician.&#xD;
&#xD;
          -  Regimen must be prescribed at FDA-approved doses for age.&#xD;
&#xD;
          -  Regimens allowed:&#xD;
&#xD;
          -  Atazanavir 300 mg po once daily plus ritonavir 100 mg po once daily, and&#xD;
&#xD;
          -  Tenofovir 300 mg po once daily, plus&#xD;
&#xD;
          -  At least one other antiretroviral medication prescribed at FDA-approved dose for age,&#xD;
             excluding other protease inhibitors and NNRTIs.&#xD;
&#xD;
          -  Ability and willingness to be contacted by study personnel daily for the two days&#xD;
             prior to the pharmacokinetics visit, to take antiretroviral medicines at the same time&#xD;
             in the morning daily for at least 3 days (one of those days being the day of the PK&#xD;
             study visit), and ability and willingness to return to the clinic the day after the&#xD;
             observed administered dose for a follow-up measurement of plasma drug concentration.&#xD;
&#xD;
          -  Ability and willingness to provide written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy.&#xD;
&#xD;
          -  Active therapy for malignancy.&#xD;
&#xD;
          -  Known presence of gastrointestinal disease that would interfere with drug&#xD;
             administration or absorption.&#xD;
&#xD;
          -  Grade 3 or higher ALT or AST.&#xD;
&#xD;
          -  Grade 3 or higher Creatinine.&#xD;
&#xD;
          -  Concurrent treatment with another protease inhibitor or a non-nucleoside analogue&#xD;
             reverse transcriptase inhibitor.&#xD;
&#xD;
          -  No evidence of anemia greater than Grade 1 according to the ATN Toxicity Table for&#xD;
             Grading Severity of Adolescent Adverse Experiences (see Chapter 11 of ATN MOGO).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Havens, MD</last_name>
    <role>Study Chair</role>
    <affiliation>MACC Fund Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital of Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California at San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California at San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Diagnostic and Treatment Center</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33316</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stroger Hospital of Cook County</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hopsital of Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Puerto Rico</name>
      <address>
        <city>San Juan</city>
        <zip>00936</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.atnonline.org</url>
    <description>Website for the Adolescent Trials Network for HIV/AIDS Interventions</description>
  </link>
  <verification_date>February 2016</verification_date>
  <study_first_submitted>January 4, 2006</study_first_submitted>
  <study_first_submitted_qc>January 5, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 9, 2006</study_first_posted>
  <last_update_submitted>February 27, 2017</last_update_submitted>
  <last_update_submitted_qc>February 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Atazanavir</keyword>
  <keyword>ritonavir</keyword>
  <keyword>tenofovir</keyword>
  <keyword>Adolescent</keyword>
  <keyword>Treatment Experienced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

